3Z Pharmaceuticals Publishes Breakthrough Study on Shared Metabolic Pathways in ADHD Therapeutics REYKJAVIK, Iceland, 24 February 2025 3Z Pharmaceuticals, a CNS-focused therapeutic development specialist, today announced the publication of a groundbreaking study in The Journal of Pharmacology and Experimental Therapeutics, unveiling novel insights into the metabolic mechanisms of ADHD treatments. This research, utilizing untargeted metabolomic...

3Z Pharmaceuticals Unveils Landmark Study Supporting Calcium Channel Blocker as a Potential Groundbreaking ADHD Therapy Reykjavik, Iceland, Feb. 17, 2025 — 3Z Pharmaceuticals today announced the publication of a transformative study in Neuropsychopharmacology, highlighting compelling scientific evidence that positions the mechanisms engaged by amlodipine, an L-type calcium channel blocker (LTCC), as a foundation for a...

3Z and biotx.ai Forge Partnership to Advance ADHD Drug Development Using AI Modelling Reykjavik, Iceland and Berlin, Aug. 18, 2023 — Reykjavik-based drug discovery company, 3Z, and Germany/US-based causal AI firm, biotx.ai, have joined forces in a strategic partnership aimed at revolutionizing ADHD drug development. By leveraging advanced AI modelling techniques, the collaboration seeks to bridge...

3Z closes $2 million funding for preclinical development of novel ADHD and Insomnia therapeutics identified by 3Z´s zebrafish drug discovery platform Reykjavik, Iceland, Jun. 20, 2022 — 3Z, a Reykjavik based drug discovery company is pleased to announce the closure of a $2 million funding round led by seasoned investors in pharmaceuticals and medical technology....